22 May 2016 - The Transparency Commission will consider the (continued) reimbursement of voriconazole (Vfend), belatacept (Nulojix), bevacizumab (Avastin), bicalutamide (Casodex), pegaspargase (Oncaspar), coagulation factor VIII (human) with von Willebrand factor (human) (Voncento), budesonide (Mikicort), vilanterol trifenatate with umeclidinium bromide (Anoro Ellipta) and pemetrexed disodium heptahydrate (Alimta).

For more details, go to: http://www.has-sante.fr/portail/upload/docs/application/pdf/2016-05/ordre_du_jour_ct_25052016.doc.pdf